Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020

$3,495.00

The Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
November 2020
Number of pages
500+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP22013

The Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in cancer diagnostics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer diagnostics partnering contract documents
  • Top cancer diagnostics deals by value

 

This report provides details of the latest Cancer Diagnostics agreements announced in the life sciences since 2014.

 

The report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.

 

The report presents financial deal term values for Cancer Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

 

The middle section of the report explores the leading dealmakers in the Cancer Diagnostics partnering field; both the leading deal values and most active Cancer Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

 

One of the key highlights of the report is that over 900 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

 

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

The initial chapters of this report provide an orientation of Cancer Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Diagnostics dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Cancer Diagnostics deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Cancer Diagnostics deals announded by that company, as well as contract documents, where available.

 

Chapter 5 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2014. The chapter is organized by specific Cancer Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

A comprehensive series of appendices is provided organized by Cancer Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Diagnostics partnering and dealmaking since 2014.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Diagnostics technologies and products.

 

Key benefits

 

Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:

 

  • In-depth understanding of Cancer Diagnostics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Cancer Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Cancer Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Cancer Diagnostics dealmakers since 2014
  • Insight into terms included in a Cancer Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020 is intended to provide the reader with an in-depth understanding and access to Cancer Diagnostics trends and structure of deals entered into by leading companies worldwide.

 

Cancer Diagnostics Partnering Terms and Agreements includes:

 

  • Trends in Cancer Diagnostics dealmaking in the biopharma industry since 2014
  • Analysis of Cancer Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Cancer Diagnostics deals
  • Access to Cancer Diagnostics contract documents
  • Leading Cancer Diagnostics deals by value since 2014
  • Most active Cancer Diagnostics dealmakers since 2014

 

In Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020 report provides comprehensive access to available deals and contract documents for over 900 Cancer Diagnostics deals.

 

Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020 report provides the reader with the following key benefits:

 

  • In-depth understanding of Cancer Diagnostics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Cancer Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Cancer Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Cancer Diagnostics dealmakers since 2014
  • Insight into terms included in a Cancer Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Cancer Diagnostics dealmaking

 

2.1. Introduction

2.2. Cancer Diagnostics partnering over the years

2.3. Most active Cancer Diagnostics dealmakers

2.4. Cancer Diagnostics partnering by deal type

2.5. Cancer Diagnostics partnering by therapy area

2.6. Deal terms for Cancer Diagnostics partnering

2.6.1 Cancer Diagnostics partnering headline values

2.6.2 Cancer Diagnostics deal upfront payments7

2.6.3 Cancer Diagnostics deal milestone payments

2.6.4 Cancer Diagnostics royalty rates

 

Chapter 3 – Leading Cancer Diagnostics deals

 

3.1. Introduction

3.2. Top Cancer Diagnostics deals by value

 

Chapter 4 – Most active Cancer Diagnostics dealmakers

 

4.1. Introduction

4.2. Most active Cancer Diagnostics dealmakers

4.3. Most active Cancer Diagnostics partnering company profiles

 

Chapter 5 – Cancer Diagnostics contracts dealmaking directory

 

5.1. Introduction

5.2. Cancer Diagnostics contracts dealmaking directory

 

Chapter 6 – Cancer Diagnostics dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Cancer Diagnostics deals by company A-Z

 

Appendix 2 – Cancer Diagnostics deals by stage of development

 

Discovery

Preclinical

Phase I

Phase II

Phase III

Regulatory

Marketed

Formulation

 

Appendix 3 – Cancer Diagnostics deals by deal type

 

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation        

Grant

Joint venture

Licensing

Litigation

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

 

Appendix 4 – Cancer Diagnostics deals by therapy area

 

Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures


Figure 1: Cancer Diagnostics partnering since 2014

Figure 2: Active Cancer Diagnostics dealmaking activity since 2014

Figure 3: Cancer Diagnostics partnering by deal type since 2014

Figure 4: Cancer Diagnostics partnering by disease type since 2014

Figure 5: Cancer Diagnostics deals with a headline value

Figure 6: Cancer Diagnostics deals with an upfront value

Figure 7: Cancer Diagnostics deals with a milestone value

Figure 8: Cancer Diagnostics deals with a royalty rate value

Figure 9: Top Cancer Diagnostics deals by value since 2014

Figure 10: Most active Cancer Diagnostics dealmakers since 2014

Figure 11: Online partnering resources

Figure 12: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2cureX, 3D Signatures, 3PrimeDx, 14M Genomics, 20/20 GeneSystems, 1717 Life Science Ventures, AB Analitica, Abbott Laboratories, Abbvie, Abcodia, Abramson Cancer Center, Accudata Systems, AccuGenomics, Accuray, Accu Reference Medical Laboratory, AceCGT Life Science, Acoustic MedSystems, ACT Genomics, Adaptiiv, Adaptive Biotechnologies, ADC Therapeutics, Admera Health, Advanced Accelerator Applications, Advanced Cell Diagnostics, Advanced Cooling Therapy, Advanced Dermatology and Cosmetic Surgery Group, Advanced Nuclear Medicine Ingredients, Aelan Cell Technologies, Aetna, Agena Bioscience, Agendia, Agilent Technologies, Agios Pharmaceuticals, AG Mednet, Akoya Biosciences, Albert Einstein Healthcare Network, Alibaba Health, Alliance Global FZ, Alliance Global Group, Almac Diagnostics, Almac Group, Alpha Imaging, Alteris, Amarantus BioSciences, Ambry Genetics, America's Choice Provider Network, American Health Imaging, American Lung Association, Amgen, Amoy Diagnostics, Amplitech, Analogic, AnchorDx, Angle, Angsana Molecular & Diagnostics, Anixa Biosciences, Anpac Bio-Medical Science, Anthem Bluecross, Apogenix, Appistry, Applied DNA Sciences, Arbor Vita, ArcherDX, Arc Medical Design, Areva Med, Arno Therapeutics (inactive since 2017), AroCell, Arquer Diagnostics, Array Biopharma, Arrow Diagnostics, ARTMS Product, Ashion Analytics, ASPiRA Labs, Aspira Scientific, Assistance Publique-Hôpitaux de Paris, Astellas Pharma, AstraZeneca, Asuragen, Atrin Pharmaceuticals, Austrian Institute of Technology, Avant Diagnostics, Avantis Medical Systems, AVEO Oncology, Avera Heart Hospital of South Dakota, Avrobio, Axela, Axella Research, Aytu BioScience, Bayer, Bayer Healthcare, Baylor Genetics, Beckman Coulter, BeiGene, Beijing InnoCare Pharma, Beijing Yuan Jian Health Management, Bertech Diagnostics, Bertin Pharma, Bethyl Laboratories, Beyondspring Pharmaceuticals, bioAffinity Technologies, Biocare Medical, Biocartis, Biocept, BioChain, Biodesix, Biofidelity, BioGemex, Biognosys, Biohealth Innovation, BioInvent, Biolidics, BioLizard, Biological Dynamics, BioMark Diagnostics, BioMarker Strategies, Biomedical Advanced Research and Development Authority, bioMerieux, BioNano Genomics, BioNova Cientifica, Biopsy Sciences, BioSkryb, Biotech-IgG, BioTheranostics, BioVendor, Biovica, Bioyong, Bird Foundation, BL&H, Black Swan Research Initiative, Bliss Biopharmaceutical, BloodCenter Of Wisconsin, Bluebee, Blue Cross Blue Shield Association, BlueCross BlueShield of Tennessee, Blue Earth Diagnostics, Blueprint Medicines, BodyCheck, Boehringer Ingelheim, Bonnie J. Addario Lung Cancer Foundation, Boreal Genomics, BostonGene, Bostwick Laboratories, Bpifrance, Bracco Imaging, Breath Diagnostics, Brigham and Women's Hospital, Bristol-Myers Squibb, Bristol-Myers Squibb Pakistan, Broad Institute, Bruker, Buck Institute for Age Research, Burning Rock, Butantan Institute, C2i Genomics, C4 Imaging, Caliber Imaging & Diagnostics, Cambridge Epigenetix, CANbridge Life Sciences, Cancer Genetics, Cancer Prevention and Research Institute of Texas, Cancer Research Institute, Cancer Research UK, Cancer Targeted Technology, Capital X-ray, Caprion Proteomics, Capsulomics, Cardinal Health, Care GB Plus, Carestream Health, Caris Life Sciences, CarThera, Case Western Reserve University, Catholic University Leuven, CBD Vida, CBLPath, CDx Diagnostics, Celgene, Cellgen Diagnostics, CellSight Technologies, Cell Signaling Technology, Celsee, Celsion, Celsius Therapeutics, Celtic Biotech, Center for Connected Health, Centogene, Centre for Imaging Technology Commercialization, Centre for Probe Development and Commercialization, Centre Leon Berard, Cepheid, Cerba HealthCare, Ceres, Cernostics, Champalimaud Foundation, Chembio Diagnostics, ChemImage, Children's Hospital Boston, Children's Hospital Los Angeles, Children's Hospital of Orange County, Chinese University of Hong Kong, Christian Doppler Research Association, Chronix Biomedical, Chugai Pharmaceutical, Circulogene, Cirrus Dx, City of Hope, Clarient, Clarity Pharmaceuticals, Clearbridge Biomedics, ClearLight Diagnostics, ClearView Diagnostics, Cleveland Clinic, Cleveland Diagnostics, Clevexel Pharma, Clinatec, Clinical Genomics, CloudHealth Genomics, Cloud Pharmaceuticals, Clovis Oncology, CNS Pharmaceuticals, Co-Diagnostics, Cobalt Healthcare Consultants, Cofactor Genomics, Cold Spring Harbor, Colorado State University, Color Genomics, Columbia University, Columbia University Medical Center, Community Medical Center, Concile, Contextual Genomics, Copenhagen University Hospital, CoreBiome, Core Diagnostics India, Cornell University, CorTechs Labs, Corvida Medical, COTA, Covidien, Crown Bioscience, Crown Dental + Medical, CSI Laboratories, CSIRO, CStone Pharmaceuticals, Cure Brain Cancer Foundation, Cure Forward, CureMetrix, Curium, CyberKnife, Cyclopharm, Cynvenio, CytoLumina Technologies, D&K Technologies, D-Eye, Daiichi Sankyo, Dako, Dana-Farber Cancer Institute, Danish Center for Strategic Research into Type 2 Diabetes, DaRui Biotech, DarwinHealth, Debiopharm, Decipher Biosciences, deCODE Genetics, Dell, Dendreon, Densitas, DermTech, Device Technologies, Devicor Medical Products, DiaCarta, DiagnoCure, Diagnoplex, Diagnostica Longwood, Diagnostic Oncology Contract Research Organization, Diaprost, Dilon Diagnostics, DNAmito, Domainex, Dr Risch, Duke-NUS Graduate Medical School Singapore, Duke University, Duke University Medical Center, DxM Diagnostico Molecular, DxTerity, DySIS Medical, Eastern Ontario Regional Laboratory Association, Eckert & Ziegler, Edico Genome, Edinburgh Molecular Imaging, EDP Biotech, Eigen, EKF Diagnostics, Elekta, Elesta, Elevation Oncology, Eleven Biotherapeutics, Eli Lilly, Emory University, Endotronix, Enigma Biomedical, Enterome Bioscience, Enzo Clinical Labs, Epic Sciences, Epigenomics, Erasmus University Medical Center, Eureka Eurostars, Eurobio, European Commission, European Health Centre Innovation, European Infrastructure for Translational Medicine, European Organization for Research and Treatment of Cancer, Eutropics Pharmaceuticals, Event Cardio Group, Everything Genetic, Exact Imaging, Exact Sciences, Exosome Diagnostics, Exosome Sciences, Factorial Diagnostics, Faron Pharmaceuticals, Federal Ministry of Education and Research (BMBF), FedMed, Feinstein Institute for Medical Research, FetoLumina Technologies, Finnish Funding Agency for Technology and Innovation (TEKES), Five Prime Therapeutics, Fluxion Biosciences, FLX Bio, FNApath, Focal Healthcare, Fondation Cancer, Fondatioun Kriibskrank Kanner, FORMA Therapeutics, Fortified Provider Network, Foundation Medicine, Fred Hutchinson Cancer Research Center, Freenome, Fscan, Fudan University, Fujifilm, Fujirebio Diagnostics, Fusion Antibodies, Galaxy Health Network, Gamma Medica, GE Healthcare, Gen-Probe, Genclis, Genecast, GeneCentric Therapeutics, GeneInsight, GeneNews, GenesisCare, Genetic Technologies, Genetron Health, Geneva University Hospitals, Genmab, Genomac Research Institute, Genome Canada, GenomeDx, Genomeon, Genomic Health, Genomics England, Genomic Testing Cooperative, Genomoncology, Genoptix, Genosity, Genotests, Georgia Institute of Technology, German Cancer Research Center, German Federal Ministry of Education and Research, Gestalt Diagnostics, Gibson Oncology, Gilead Sciences, GIMDx, GlaxoSmithKline, GLG Pharma, Glide, Global Cancer Diagnostics, Global Discovery Biosciences, Global Medical Solutions, Gloval Specimen Solutions, Glycotest, GNS Healthcare, GNYHA Services, Goodwin Biotechnology, Gotect Diagnostic, Government of Canada, Grail, Group Vida, Grupo Ferrer, Guardant Health, Guerbet, Guided Therapeutics, Guided Therapy Systems, Gyros Protein Technologies, Hainan Sinotau Pharmaceutical, HalioDx, HALO Diagnostics, Halo Dx, Halozyme Therapeutics, Harvard Medical School, Harvard Pilgrim Health Care, HealthCare Konnect, Health Diagnostics Laboratory, HealthMyne, HealthTrust, Hebrew University of Jerusalem, Helio Health, Helomics, Hemogenomics Pharma, Hengrui Therapeutics, Henlius Biotech, Henry Ford Health System, Highmark Blue Shield, Hitachi, Hitachi Aloka Medical, Hitachi Medical Systems Europe, Hoag Memorial Hospital Presbyterian, Hologic, Horizon 2020, Horizon Discovery, Hospital Services, HTG Molecular Diagnostics, Human Longevity, Huntsman Cancer Institute, Hvidovre Hospital, Hybridyne Imaging Technologies, IBA Molecular Imaging, Ibex Medical Analytics, iBIO Institute’s PROPEL Center, IBL America, IBM, IBM Watson Health, iCAD, Icahn School of Medicine at Mount Sinai, Idaho Urologic Institute, Idengene, Idera Pharmaceuticals, Illumina, Image Analysis, ImaginAb, Imaging Associates, Imanis Life Sciences, Imaware, Imegen, ImmunID Technologies, ImmunoCellular Therapeutics, ImmunoGen, Immunovia, ImpediMed, Imperial College London, IncellDx, Incyte, Indiana University, Indigo Biosciences, Indivumed, Inflammatory Breast Cancer Research Foundation, Inform Genomics, Inhibrx, Inivata, Innovate UK, Innovative Diagnostic Laboratory, Inovio Pharmaceuticals, Inserm, Inserm Transfert, InSightec, Insight Genetics, Institut Català d'Oncologia, Institut Curie, Institute for Bioscience and Biotechnology Research, Institute of Biophysics, Institute of Cancer Research, Institut Gustave Roussy, Instituto Diagnostico Varelli, IntegraGen, Integrated Biobank of Luxembourg, Integrated Diagnostics, Integrated DNA Technologies, Intensity Therapeutics, Intermountain Healthcare, International Myeloma Foundation, Interpace Diagnostics, Interpace Diagnostics Group, Intezyne, Invenra, inviCRO, Invitae, InVivoScribe, ION Solutions, IPMD, Ironwood Pharmaceuticals, IRX Therapeutics, ISIS Innovation, Isotope Technologies Garching, Isotopia Molecular Imaging, Istituto Diagnostico Varelli, Item, ITEM Medical Technologies, ITM Isotopen Technologien, iVu Imaging, Janssen-Cilag, Janssen Biotech, Janssen Diagnostics, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Jazz Pharmaceuticals, Jiangsu Hengrui Medicine, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, John Wayne Cancer Institute, JTS Health Partners, Jubilant DraxImage, Juno Therapeutics, Kailos Genetics, Kaiser Foundation Research Institute, Kaiser Permanente, Kalgene Pharmaceuticals, Karolinska Institute, Keck School of Medicine of USC, KEW, Kindstar Globalgene Technology, Kite Pharma, Kiyatec, Knight Cancer Institute, Knight Diagnostic Laboratories, Konica Minolta, Korea Pharma, KUB Technologies, Kura Oncology, Lab21, Labcyte, Lab Genomics, Laboratory Corporation of America, Lantheus Holding, Lee Moffitt Cancer Center, Lehigh University, Leica Biosystems, Leicester University, Leiden University, LEO Pharma, Les Laboratoires Servier, Lexent Bio, LifeLabs Medical Laboratory Services, LifeSensors, Life Technologies Corporation, LifeX Ventures, Lightpoint Medical, Li Ka Shing Foundation, LineaRx, LI Path, Loxo Oncology, Lucid Diagnostics, LumaMed, Lumicell, Luminex, Lunatus, Lund University, Lung Cancer Alliance, Lurie Children's Hospital of Chicago, MabVax Therapeutics, Macquarie University, Magle Chemoswed, Magnetic Insight, Major Health Partners, Mammoth Biosciences, Manhattan Scientifics, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mauna Kea Technologies, Mavig, Mayo Clinic, MD Anderson Cancer Center, MDL Information Systems, MDNA Life Sciences, MDxHealth, med fusion, MEDIAN Technologies, Medical Imaging, Medical Prognosis Institute, Medical University of Graz, Medical University of South Carolina, Medidata Solutions, Medipath, Mediso, Medivation, MedPac Asia Pacific, medPhoton, Medx, MELA Sciences, Memorial Sloan Kettering Cancer Center, Menarini, Merck and Co, Merck KGaA, Merck Serono, Merck Sharpe & Dohme, Merit Medical Systems, Merrimack Pharmaceuticals, Metabiomics, Metafora Biosystems, Metamark Genetics, Metaoptima Technology, MetaStat, Mevion Medical Systems, MicroConstants, Micromedic Technologies, Microsoft, Milburn Foundation, Milenia Labs, Millennium Medical Devices, MindPeak, Ministry of Health (Turkey), Minogue Medical, Minomic, MIODx, Miraca Life Sciences, Miragen Therapeutics, Mirati Therapeutics, MiRXES, Mitra Biotech, Moldionics, Molecular Health, MolecularMD, Molecular Response, Monteris Medical, Moores Cancer Center, Morphotek, Mount Sinai Health System, Mount Sinai Services, Movember Foundation, MRI Interventions, MRM Proteomics, MultiPlan, Multiple Myeloma Research Foundation, Munich Leukemia Laboratory, Myeloma Health, Myelopro Diagnostics and Research, My Gene Counsel, Myriad Genetics, N-of-One, Nano-X Imaging, Nanobeak, NanoMab Technology, Nanopharmacia, NanoString Technologies, NantBioScience, NantHealth, NantWorks, NASA, Natera, National Cancer Centre Singapore, National Cancer Institute, National Cancer Institute of Mexico, National Healthcare Services (NHS), National Institute for Public Health and the Environment, National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Imaging and Bioengineering, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health, National Organization for Rare Disorders, National Physical Laboratory, National Science Foundation, National Taiwan University Hospital, National Ultrasound, Natural Sciences and Engineering Research Council of Canada, Navidea Biopharmaceuticals, Nemucore Medical Innovations, Neogenomics, NEO New Oncology, NetScientific, New Horizon Health, New Jersey Urology, Newmars Group, Nihon Medi-Physics, Ninepoint Medical, NM Genomix, Norgen Biotek, Norgine, Norsk medisinsk syklotronsenter, Northeastern University, North Shore-LIJ Cancer Institute, Northwestern University, Notable Labs, Novartis, NovellusDx, Novigenix, Novogene, Nuclea Biotechnologies, Nucleix, NueHealth, NuProbe, NuView Life Sciences, Ochin, OmniSeq, Oncgnostics, Oncimmune, Oncimmune Ltd, OncoBeta, OncoCyte, OncoDNA, OncoGenesis, OncoHost, Oncology Venture, OncoNano Medicine, OnCore Biopharma, OncoTracker, OncoVision, Ono Pharmaceutical, Ontario Cancer Biomarker Network, Ontario Institute for Cancer Research, OPKO Health, OracleBio, Orebro University, Oregon Health Sciences University, ORIG3N, OrigiMed, Orot+, Oslo University Hospital, Ospedale Pediatrico Bambino Gesu, Otsuka, OvaGene Oncology, Ovarian Cancer Institute, Owlstone Medical, Oxford BioTherapeutics, P-cure, Panacea Pharmaceuticals, PapGene, Paradigm, Paralax Life Science Group, Paris Descartes University, PathAI, PathGroup, Pathnova Laboratories, Pathway Diagnostics, Patient-Centered Outcomes Research Institute (PCORI),, PAVmed, Pax Neuroscience, Pentax, PentixaPharm, Personal Genome Diagnostics, Personalis, Personalized Medicine Initiative (PMI), PersonalizeDx, Perthera, PETNET Solutions, Pfizer, Phase Holographic Imaging, Phi Life Sciences, Philips, Philips Healthcare, Phoenix Molecular Designs, Photocure ASA, Physician’s Choice Laboratory Services, PierianDx, Pierre Fabre, Pippa Mann, Planet Innovation, Planmed, Poitiers University, Positive Bioscience, Precipio Diagnostics, Precision for Medicine, Precision Pathology Services, Predicine, Predictive Technology Group, PrediLife, Premas Life Sciences, PREMIA Holdings, Premier Inc, Prenetics, Preora Diagnostics, Prescient Medical, Prime Healthcare Services, Prime Health Services, Profound Medical, Progenetics, Progenics Pharmaceuticals, ProNova, Propper Manufacturing, Proscia, Prostate Cancer Foundation (PCF), Protagen, Protea Biosciences, Providence Saint John's Health Center, Provista Diagnostics, Puma Biotechnology, Pure MHC, QED Therapeutics, Qiagen, Qualigen, Quanterix, Queensland University of Technology, Queens University Belfast, Quest Diagnostics, QuiO Technologies, R-Biopharm, Radboud University Nijmegen Medical Centre, Radiomedix, Radius Health, RadNet, Raiing Medical, Rainbow Genomics, RAW, RayBiotech, RaySearch Laboratories, RedPath Integrated Pathology, Renji Hospital, Research Center for Molecular Medicine of the Austrian Academy of Sciences, ResearchDx, Resolution Bioscience, Response Genetics, RiboMed, Riverside Research, Robert H. Lurie Comprehensive Cancer Center, Roche, Rosetta Genomics, Roswell Park Cancer Institute, ROTOP Pharmaka, Royal Marsden Hospital, Royal Philips Electronics, Rutgers University, SAGA Diagnostics, Saladax Biomedical, Sanofi, Sarah Cannon Research Institute, Sayre Therapeutics, SBRI Healthcare, Scancell, Scandion Oncology, SciBase, Scienion, Scintomics, Seattle Children's Hospital, Seattle Childrens Research Institute, Seattle Genetics, Sebia, Sectra, Seegene, Seibersdorf Laboratories, Selexis, Sengenics, SEngine Precision Medicine, Sensus Healthcare, Sequenom, Sequenta, Seracare Life Sciences, Shanghai Fosun Long March Medical Science, Shanghai Pharmaceutical, Sheba Medical Center, Shenzhen Chipscreen Biosciences, Sherlock Biosciences, Shuwen Biotech, Siemens, Siemens Healthcare Diagnostics, Signal Genetics, Signet Medical Solutions, Siloam Biosciences, SimonMed Imaging, Singlera Genomics, Sintact Medical Systems, Sirtex Medical, Sividon Diagnostics, Skane University Hospital, SkinCure Oncology, SkylineDX, Skyline Medical, Skyline Urology, Small Business Innovation Research, Smart Medical Systems, Smilow Cancer Hospital at Yale-New Haven (SCH), Sofie Biosciences, SolaranRx, Solis Mammography, Sonic Healthcare, Sophia Genetics, Sorgente, Soricimed Biopharma, Sorrento Therapeutics, SouthGenetics, Southwest Gynecological Pathology Lab, Spectrum Health, Spectrum Pharmaceuticals, SpePharm, Sphingotec, Sprint Biosciences, SRI International, SST Group, St. Jude Children's Research Hospital, Stanford Health Care, Stanford University, Stanford University School of Medicine, Strata Oncology, STRATIFYER Molecular Pathology, Stratify Genomics, Stratose, Streck Laboratories, Stroke Detection Plus, Sunnybrook Health Sciences Centre, SuperSonic Imagine, Surrey Cancer Research Institute, Susan G. Komen for the Cure, SweLife, Swift Biosciences, Swiss Institute of Allergy and Asthma Research, SWOG Cancer Research, Syapse, SYGNIS Pharma, Synaptive Medical, Sysmex, Sysmex Inostics, TaiRx, TaiRx US, Take2, Takeda Pharmaceutical, Tampere University Hospital, Targos, Tasly Pharmaceuticals, Technology Transfer Accelerator, TeleMammography Specialists, Telik, Telix Pharmaceuticals, Telo Genomics, Temple University, Tempus, Teneovita Medical, Tesaro, TestAnalytika, Teva Pharmaceutical Industries, Texas A&M University, The Binding Site, The Christie, The Fleury Group, The Haematological Malignancy Research Network, The Parker Institute For Cancer Immunotherapy, Theraclion, Theradiag, Theragnostics, Theranostics Health, Thermo Fisher Scientific, Thomas Jefferson University, Three Rivers Provider Network, Threshold Pharmaceuticals, Tiziana Life Sciences, TNK Therapeutics, Tocagen, Todos Medical, Tokai Pharmaceuticals, Tolero Pharmaceuticals, Toronto Innovation Acceleration Partners, Tor Vergata University Hospital, TP Therapeutics, TRACON Pharmaceuticals, Transgenomic, Translational Drug Development, Translational Genomics Research Institute, TrialJectory, TrovaGene, TTFactor, Tuberous Sclerosis Alliance (TS Alliance), Tulane University, Turgut Ilaclari, Turku PET Center, Tymora Analytical Operations, uBiome, Ultivue, Unified Women's Clinical Research, Unilabs, UnitedHealthcare, United Imaging Healthcare, United States Military Cancer Institute, University Ann & Robert H. Lurie Children’s Hospital, University City Science Center, University College London, University Health Network, University Hospital Bispebjerg, University Hospital of Leuven, University Medical Center Hamburg-Eppendorf, University of Arizona, University of Arkansas, University of Bonn, University of California, University of California, San Diego, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Chicago, University of Colorado, University of Colorado Denver, University of Florida, University of Greifswald, University of Heidelberg, University of Leeds, University of Louisville, University of Massachusetts Medical School, University of Melbourne, University of Michigan, University of Minnesota, University of Oxford, University of Pennsylvania, University of Rostock, University of Sheffield, University of Sunderland, University of Surrey, University of Texas Health SCience Center at San Antonio, University of Tokyo, University of Torino, University of Toronto, University of Washington, UPMC, Uppsala University Hospital, Urology Centers of Alabama, Urology San Antonio, USC Norris Comprehensive Cancer Center, US Oncology, US Oncology Research, US Radiology Specialists, Vanderbilt-Ingram Cancer Center, Vantage Health, Varian Medical Systems, Vect-Horus, Vector Oncology, Velocity Medical Solutions, Ventana Medical Systems, Veracyte, Verisante Technology, Vermillion, Viatar CTC Solutions, ViewRay, Vigilant Biosciences, Virginia Tech Intellectual Properties, Vitatex, Vizient, VolitionRX, Volpara Solutions, VuCOMP, Vyriad, WaferGen Biosystems, Wallace H. Coulter Foundation, Washington University in St Louis, Weihai Weigao Medical Devices, Weill Cornell Medical College, Wellcome Trust Sanger Institute, Whiterabbit, Worldwide Innovative Network (WIN) in personalized cancer medicine Consortium, Wuhan Kindstar Diagnostics, WuXi NextCODE Genomics, WuXi PharmaTech, Xiamen Encheng Group, Xylonix, Yale School of Medicine, Yitu Medical, Ymir Genomics, YourRad, Zebra Medical Vision, Zenalux Biomedical, Zenon Biosystem, Zenosense, Zero Cancer Research Fund, Zionexa, ZoBio, Zomedica, zPREDICTA

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!